We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

PCR-Based Molecular Platform to Enable Drastically Faster Bacterial Infection Diagnosis

By LabMedica International staff writers
Posted on 08 Jun 2023
Print article
Image: Molecular Culture® technique enables drastically faster and more accurate bacterial diagnostics (Photo courtesy of inbiome)
Image: Molecular Culture® technique enables drastically faster and more accurate bacterial diagnostics (Photo courtesy of inbiome)

A new novel PCR-based molecular platform provides a significant advancement in diagnosing bacterial infections by offering an alternative to traditional culture methods and outperforming newer methods such as sequencing on the time and cost front, while also matching the scope of other PCR tests.

Inbiome’s (Amsterdam, the Netherlands) Molecular Culture technique significantly speeds up and improves the precision of bacterial diagnostics compared to traditional culture. This revolutionary diagnostic technique has the capability to identify the vast majority of bacterial species through a single test. It is particularly tailored to deliver accurate results from invasively collected samples, such as cerebrospinal fluid, pus, and joint aspirates. Unlike culture or traditional PCR-based methods, Molecular Culture is not selective, which means medical professionals don't need to decide in advance which bacteria to search for. Since it is based on DNA detection, it can easily identify or detect bacteria that are unknown, uncultivable or have been treated with antibiotics.

Compared to conventional tests, Molecular Culture is more sensitive and precise. It accurately diagnoses almost double the number of positive samples, significantly reducing the prevalence of false negatives often associated with traditional testing. This leads directly to more informed treatment decisions, consequently improving patient outcomes. Moreover, the diagnostic process is quick, efficient, and simple. It delivers reliable and actionable results within four hours without the need for specialized equipment or bioinformatics pipelines. This means patients recover more quickly, complications are minimized, and the duration of hospital stays is substantially reduced. Currently, Molecular Culture is being utilized in several hospitals in the Netherlands, demonstrating exceptional results.

Related Links:
inbiome

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Typhoid Rapid Test
OnSite Typhoid IgG/IgM Combo Rapid Test
New
Chlamydia Trachomatis Assay
Chlamydia Trachomatis IgG

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more